131-I-omburtamab administration
toxicity
cRIT with 131-I-Omburtamab was delivered as previously described: a test dose (2 milliCurie [mCi]/injection), then if tolerated, followed by 1 or 2 monthly injections (10-70 mCi/injection) with dosing based on a phase I dose-escalation level at the time of patient entry. Clinical status, vital signs and neurologic examination were monitored overnight. Repeat therapy injections were administered in the absence of grade three or four toxicity [